# Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

> **NCT05956509** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 1 (actual)

## Conditions studied

- Upper Limb Spasticity

## Interventions

- **BIOLOGICAL:** ABBV-950
- **BIOLOGICAL:** BOTOX
- **DRUG:** Placebo for ABBV-950

## Key facts

- **NCT ID:** NCT05956509
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-12
- **Primary completion:** 2024-06-02
- **Final completion:** 2024-06-02
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05956509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05956509, "Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05956509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*